Protagonist Therapeutics granted two U.S. patents for peptide drug candidates
Protagonist Therapeutics announced that two new U.S. patents have been issued for the company's novel peptide drug candidates, PTG-100 and PTG-300. The first patent covers methods of treating inflammatory bowel diseases with PTG-100, an orally stable alpha-4-beta-7 integrin peptide inhibitor. PTG-100 is currently in Phase 2b testing in patients with moderate-to-severe, active ulcerative colitis. The new patent adds to two previously granted U.S. patents which also provide protection for the company's alpha-4-beta-7 integrin peptide inhibitors, including PTG-100. The second patent covers peptide analogues of hepcidin, including PTG-300, and related pharmaceutical compositions. PTG-300, the company's lead peptide hepcidin mimetic, recently completed a Phase 1 clinical study in healthy volunteers. Protagonist plans to initiate Phase 2 trials of PTG-300 in patients with beta-thalassemia and myelodysplastic syndrome during 2018.